It marks the first of seven peptide drugs the FDA's Pharmacy Compounding Advisory Committee will address on Thursday and Friday.
Roche’s Vabysmo disappointed investors again. In the second quarter, the eye drug’s sales of about 1.04 billion Swiss francs ($1.27 billion) missed analysts’ expectations by 7.1%. | On an investor ...
As the recent reshoring zeal rolls on in the United States, BeOne Medicines is beefing up its flagship manufacturing and R&D campus in New Jersey to the tune of $300 million. | As the recent ...
Johnson & Johnson has unveiled massive phase 3 survival data for its dual bispecific combination in earlier-line multiple ...
In a landmark moment for its oncology ambitions, GSK has secured FDA approval for Jideytro (zidesamtinib) as the first ...
The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, ...
While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the ...
Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become the first drug to specifically ...
A U.K. marketing watchdog has reprimanded Sanofi for using “a highly misleading interpretation of data” to make disparaging ...
Amgen has agreed to a $74 million settlement with investors who allege that the company hid a massive U.S. tax bill from the ...
Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has ...
Aerospace technology company Redwire—which has partnered with Bristol Myers Squibb and Eli Lilly to test drug manufacturing in space—has opened a new 30,000 square foot research and microgravity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results